Results 71 to 80 of about 22,453,438 (395)

The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery

Life, 2020
(1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies.
Lisa Schmitz, Belinda Berdien, Edith Huland, Petra Dase, Karin Beutel, Margit Fisch, Oliver Engel   +6 more
doaj   +1 more source

Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer

Molecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti, Shingo Inagaki, Tuyen Thuy Bich Ho, Akihiro Seki, Keiko Yoshida, Kosuke Satomura, Yoshio Sakai, Shuichi Kaneko, Taro Yamashita   +8 more
wiley   +1 more source

Structure of the interleukin-2 tyrosine kinase Src homology 2 domain; comparison between X-ray and NMR-derived structures [PDF]

, 2012
The crystal structure of the interleukin-2 tyrosine kinase Src homology domain (Itk SH2) is described and it is found that unlike in studies of this domain using NMR spectroscopy, cis-trans-prolyl isomerization is not readily detected in the crystal ...
Andreotti, Amy, Andreotti, Amy, Fulton, D. Bruce, Ginder, Nathaniel, Honzatko, Richard, Hoy, Julie, Joseph, Raji, Nix, Jay   +7 more
core   +3 more sources

Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia

Cells, 2020
Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary ...
Dipnarine Maharaj, Gayathri Srinivasan, Maria M. Abreu, Meng-Wei Ko, Anahid Jewett, Jacqueline Gouvea   +5 more
doaj   +1 more source

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

New England Journal of Medicine, 2011
BACKGROUND Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes.
D. Schwartzentruber, D. Lawson, J. Richards, R. Conry, Donald M Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. Kendra, R. White, Rene C. Gonzalez, T. Kuzel, B. Curti, P. D. Leming, E. Whitman, J. Balkissoon, D. Reintgen, H. Kaufman, F. Marincola, M. Merino, S. Rosenberg, P. Choyke, D. Vena, P. Hwu   +25 more
semanticscholar   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study [PDF]

, 2006
Objective: The objective of the trial was to evaluate in a pilot setting the safety and efficacy of interleukin-2 (IL-2) therapy when used without concomitant antiretroviral therapy as a treatment for HIV infection.
Abrams, Ann Sullivan, Carr, Carr, Carr, Christian Herzmann, Clive Loveday, Connelly, Crespo-Fierro, Davey, Davey, Davey, Dewar, Emery, Emery, Emery, George Janossy, H. Clifford Lane, Handan Wand, Jorge A Tavel, Kovacs, Kovacs, Lederman, Levy, Lisa Fosdick, Losso, Margaret A Johnson, Mark Nelson, Martin Fisher, Matthews, Mercolino, Mike Youle, Palella, Pillay, Pozniak, Richard T Davey, Ruxrungtham, Sean Emery, Sereti, Sereti, Smith, Stein, Urdea, Verbeke, Yeni   +44 more
core   +2 more sources

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV30 trial

Molecular Oncology, Volume 19, Issue 5, Page 1436-1451, May 2025.
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge   +11 more
wiley   +1 more source

Evaluation of in vitro Effect of Pyocyanine Pigment on Interleukin-2 Secretion from Peripheral Blood Mononuclear Cells in Cancer Patients

Iranian Journal of Medical Microbiology, 2021
Background and Objective: The pyocyanine pigment in Pseudomonas aeruginosa stimulates blood cells to secrete IL-2. IL-2 cytokine is an activator of cytotoxic T cells and natural killer cells.
Anahita Mohseni, Afsoon Shariat
doaj  

Exploiting a natural conformational switch to engineer an Interleukin-2 superkine

Nature, 2012
The immunostimulatory cytokine interleukin-2 (IL-2) is a growth factor for a wide range of leukocytes, including T cells and natural killer (NK) cells.
A. M. Levin, D. Bates, A. Ring, C. Krieg, Jack T. Lin, L. Su, Ignacio Moraga, M. E. Raeber, G. Bowman, Paul A. Novick, V. Pande, C. Fathman, O. Boyman, K. Garcia   +13 more
semanticscholar   +1 more source